State

US Virgin Islands product recalls

73,824 recalls have nationwide distribution and so reach US Virgin Islands. 178 additional recalls listed US Virgin Islands specifically in their distribution scope.

What the numbers show

Total: 178
Critical: 12
Severe: 39
Most recent: 2026-10-21

Of the 178 recalls naming US Virgin Islands we have scored against our rubric, 12 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 39 (22%) are Severe.

Which agencies issued them

These figures cover only the 178 recalls whose distribution notice names US Virgin Islands specifically. The 73,824 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

54201–54225 of 74002

SevereFDA (Drugs)·D-699-2015·2015-04-29
Attix Pharmaceuticals Recalls Gemfibrozil Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Gemfibrozil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Gemfibrozil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-880-2015·2015-04-29
Attix Pharmaceuticals Recalls Rifaximin API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Rifaximin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Rifaximin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-911-2015·2015-04-29
Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-548-2015·2015-04-29
Attix Pharmaceuticals Recalls Bromhexine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Bromhexine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Bromhexine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-742-2015·2015-04-29
Attix Pharmaceuticals Recalls Ketoprofen Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling ketoprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Ketoprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-908-2015·2015-04-29
Attix Pharmaceuticals Recalls Sulfisoxazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sulfisoxazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Sulphafurazole (Sulfisoxazole) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-656-2015·2015-04-29
Attix Pharmaceuticals Recalls Estriol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Estriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.
Product
Estriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-749-2015·2015-04-29
Attix Pharmaceuticals Recalls Lanthanum Carbonate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Lanthanum Carbonate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Lanthanum Carbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-790-2015·2015-04-29
Attix Pharmaceuticals Recalls Methyl Folate Calcium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methyl Folate Calcium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Methyl Folate Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-831-2015·2015-04-29
Attix Pharmaceuticals Recalls Pantoprazole Sodium Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Pantoprazole Sodium Monohydrate repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Pantoprazole Sodium Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-527-2015·2015-04-29
Attix Pharmaceuticals Recalls Atomoxetine HCl Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Atomoxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Atomoxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-842-2015·2015-04-29
Attix Pharmaceuticals Recalls Pimecrolimus Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pimecrolimus active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pimecrolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-678-2015·2015-04-29
Attix Pharmaceuticals Recalls Flucytosine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Flucytosine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Flucytosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-888-2015·2015-04-29
Secnidazole API Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Secnidazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Secnidazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-600-2015·2015-04-29
Attix Pharmaceuticals Recalls Cortisone Acetate Micronized Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cortisone Acetate Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cortisone Acetate Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-745-2015·2015-04-29
Attix Pharmaceuticals Recalls L-Asparaginase Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling L-Asparaginase active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
L-Asparaginase active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-682-2015·2015-04-29
Fluorescein Sodium Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluorescein Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Fluorescein Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-949-2015·2015-04-29
Vancomycin HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Vancomycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Vancomycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-704-2015·2015-04-29
Attix Pharmaceuticals Recalls Heptaminol Hydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Heptaminol Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Heptaminol Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-775-2015·2015-04-29
Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-555-2015·2015-04-29
Attix Pharmaceuticals Recalls Calcipotriene Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Calcipotriene active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Calcipotriene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-590-2015·2015-04-29
Attix Pharmaceuticals Recalls Cisplatin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling cisplatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cisplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-891-2015·2015-04-29
Sertraline HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Sertraline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Sertraline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-832-2015·2015-04-29
Attix Pharmaceuticals Recalls Paromomycin Sulphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Paromomycin Sulphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Paromomycin Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-672-2015·2015-04-29
Attix Pharmaceuticals Recalls Famotidine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling famotidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Famotidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide